Why the Next Science (ASX:NXS) share price opened 40% higher

The Next Science Ltd (ASX: NXS) share price is shooting for the moon after the company’s latest announcement. Click on to find out why.

| More on:
Rising healthcare ASX share price represented by doctor giving thumbs up

Image source: Getty Images

Next Science Ltd (ASX: NXS) shares are shooting for the moon in Monday’s session. When trading commenced, shares in the medical company opened almost 41% higher at $2.00. They then continued on to a new 52-week high of $2.06 before partially retreating.

At the time of writing, the Next Science share price is trading at $1.77, up 24.65%. By comparison, the All Ordinaries Index (ASX: XAO) is currently 0.03% lower.

Today’s positive price movement comes as the company announced it has received clearance from the United States Food and Drug Administration (FDA) to sell one of its products in the US.

Let’s take a closer look at today’s announcement.

What’s boosting the Next Science share price?

In a statement to the ASX, Next Science says it has received 501(k) clearance for its “XPerience™ No Rinse Antimicrobial Solution as a medical device in the United States.” According to the company, XPerience is inserted into a surgical site, which is then closed, to fight infection for up to several hours afterwards.

Next Science says the product can be used in “every open surgery case”. Initially, however, the company will target its product for use in shoulder, hip, knee, podiatry and trauma surgeries.

The company says sales in the US will commence immediately. Investors are reacting well to the news, judging by the Next Science share price.

According to the statement, surgical site infection (SSI) is the second-largest cause of hospital-acquired infection in the US. Next Science says, “The use of XPerience No Rinse Antimicrobial Solution can help prevent costly hospital re-admissions.”

Management commentary

Next Science managing director Judith Mitchell said of today’s update:

With an estimated 234 million surgical procedures undertaken globally per annum, XPerience provides an enormous opportunity to help reduce infection, antimicrobial resistance and save lives while reducing expenses for health systems arising from postsurgical infections.

Surgical site infections

According to John Hopkins University, the chance of developing an SSI after surgery is anywhere from 1% to 3%. SSIs usually occur 30 days after surgery and there are three types:

  1. Superficial SSI – infection occurs in the skin, where the initial cut was made.
  2. Deep incisional SSI – infection occurs in the muscle and tissue around it, underneath the cut area.
  3. Organ or space SSI – infection occurs anywhere in the body that is not the skin or muscle.

Risk factors for developing SSIs include being overweight, smoking, having cancer or diabetes, and undergoing emergency surgery.

Next Science share price snapshot

Over the past 12 months, the Next Science share price increased 5.35%. However, over the last three months, the company’s value has appreciated by around 57%. Its 52-week high before today was $1.86 and its yearly low is $1.10.

Next Science has a market capitalisation of $280.5 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nexus Energy Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

What’s going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Virtus share price holds steady despite 30% earnings fall

Shareholders are staying loyal with a looming acquisition.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance
Healthcare Shares

Own Medibank shares? Here’s what to watch over the coming months

What are the key dates for Medibank in 2022?

Read more »

A happy woman smiles as she looks at a tablet in a room with green plantlife around her. She is also wearing a green shirt representing the rising Polynovo share price
Share Gainers

Why is the Polynovo share price surging 35% in 5 days?

Polynovo shares have sprouted shoots of green in recent weeks.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Rhythm Biosciences share price lifts 5% on TGA news

The company is hoping to market and sell its cancer test kit in Australia this year.

Read more »